The Gold Standard is a workplace- based program that focuses on lowering the risk of cancer.
The Life Sciences Consortium (LSC) brings together oncology companies to accelerate discovery and development of new therapies for all cancer patients. Visit Website
President George HW Bush appointed Chris Viehbacher Chairman of the CEO Roundtable on Cancer in 2011.
Chris is the Managing Partner of Gurnet Point Capital, a Boston-based investment fund. He is also a member of the Board of Pure Tech Health plc and is the Chairman of Vedanta, a Pure Tech portfolio company. He is a member of the Board of Trustees of Northeastern University.
Chris is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.
Prior to joining Sanofi, Chris spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a Member of the Board of Directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. Chris began his career with Price Waterhouse after graduating with a degree in Commerce at Queen's University in Canada.
Chris has been a strong advocate for the healthcare industry. Current and past advocacy roles include:
Chris has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario.
Chris has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Legion d’Honneur.
Chris is married with three children. He fluently speaks English, French and German.